文献速递药疹与重症皮肤不良反应

血浆置换与免疫球蛋白作为SJS/TEN系统皮质类固醇治疗无效后一线治疗的比较

Evaluation of Plasmapheresis vs Immunoglobulin as First Treatment After Ineffective Systemic Corticosteroid Therapy for Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
PubMed 文献 · JAMA Dermatol · 2023-01-01

这项回顾性队列研究利用日本全国行政索赔数据库,比较了Stevens-Johnson综合征和中毒性表皮坏死松解症(SJS/TEN)患者在接受全身性皮质类固醇治疗无效后,首先接受血浆置换或首先接受静脉注射免疫球蛋白(IVIG)的临床结局。倾向评分重叠加权显示,两组住院死亡率无显著差异(18.3% vs 19.5%;OR 0.93;95%CI 0.38-2.23;P=0.86),但血浆置换优先组的住院时间更长(45.3 vs 32.8天;差值12.5天;95%CI 0.4-24.5天;P=0.04),医疗费用更高(34,262美元 vs 23,054美元;差值11,207美元;95%CI 2,789-19,626美元;P=0.009)。

要点

  • 在SJS/TEN患者系统皮质类固醇治疗无效后,首先血浆置换与首先IVIG的住院死亡率无显著差异(18.3% vs 19.5%;OR 0.93;95%CI 0.38-2.23;P=0.86)。
  • 血浆置换优先组住院时间较IVIG优先组长12.5天(45.3 vs 32.8天;95%CI 0.4-24.5天;P=0.04)。
  • 血浆置换优先组医疗费用较IVIG优先组高11,207美元(34,262 vs 23,054美元;95%CI 2,789-19,626美元;P=0.009)。

核心结论

  • 这项全国性回顾性队列研究发现,SJS/TEN患者系统皮质类固醇治疗无效后,首先给予血浆置换相比首先给予IVIG并无显著获益,但血浆置换优先组的医疗费用和住院时间更高。

研究设计与样本

  • 回顾性队列研究,使用日本全国行政索赔数据库(涵盖超过1200家医院),研究时间为2010年7月至2019年3月。
  • 纳入在住院3天内开始至少1000 mg/d甲泼尼龙等效全身皮质类固醇治疗后接受血浆置换和/或IVIG治疗的SJS/TEN住院患者。
  • 血浆置换优先组53例,IVIG优先组213例(平均[SD]年龄56.7[20.2]岁;女性152例[57.1%])。
  • 数据分析时间为2020年10月至2021年5月。

主要发现

  • 倾向评分重叠加权显示,血浆置换优先组与IVIG优先组的住院死亡率无显著差异(18.3% vs 19.5%;OR 0.93;95%CI 0.38-2.23;P=0.86)。
  • 与IVIG优先组相比,血浆置换优先组住院时间更长(45.3 vs 32.8天;差值12.5天;95%CI 0.4-24.5天;P=0.04)。
  • 与IVIG优先组相比,血浆置换优先组医疗费用更高(34,262美元 vs 23,054美元;差值11,207美元;95%CI 2,789-19,626美元;P=0.009)。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are severe cutaneous adverse reactions, and patients with SJS/TEN frequently require intensive care. However, there is limited evidence on the clinical outcomes of immunomodulating therapy, including plasmapheresis and intravenous immunoglobulin (IVIG) in patients with SJS/TEN. OBJECTIVE: To compare clinical outcomes of patients with SJS/TEN who were treated with plasmapheresis first vs IVIG first after ineffective systemic corticosteroid therapy. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from a national administrative claims database in Japan that included more than 1200 hospitals and was conducted from July 2010 to March 2019. Inpatients with SJS/TEN who received plasmapheresis and/or IVIG therapy after initiation of at least 1000 mg/d of methylprednisolone equivalent systemic corticosteroid therapy within 3 days of hospitalization were included. Data were analyzed from October 2020 to May 2021. EXPOSURES: Patients who received IVIG or plasmapheresis therapy within 5 days after initiation of systemic corticosteroid therapy were included in the IVIG- and plasmapheresis-first groups, respectively. MAIN OUTCOMES AND MEASURES: In-hospital mortality, length of hospital stay, and medical costs. RESULTS: Of 1215 patients with SJS/TEN who had received at least 1000 mg/d of methylprednisolone equivalent within 3 days of hospitalization, 53 and 213 patients (mean [SD] age, 56.7 [20.2] years; 152 [57.1%] women) were included in the plasmapheresis- and IVIG-first groups, respectively. Propensity-score overlap weighting showed no significant difference in inpatient mortality rates between the plasmapheresis- and IVIG-first groups (18.3% vs 19.5%; odds ratio, 0.93; 95% CI, 0.38-2.23; P = .86). Compared with the IVIG-first group, the plasmapheresis-first group had a longer hospital stay (45.3 vs 32.8 days; difference, 12.5 days; 95% CI, 0.4-24.5 d; P = .04) and higher medical costs (US $34 262 vs $23 054; difference, US $11 207; 95% CI, $2789-$19 626; P = .009). CONCLUSIONS AND RELEVANCE: This nationwide retrospective cohort study found no significant benefit to administering plasmapheresis therapy first instead of IVIG first after ineffective systemic corticosteroid treatment in patients with SJS/TEN. However, medical costs and length of hospital stay were greater for the plasmapheresis-first group.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Miyamoto Y, Ohbe H, Kumazawa R, et al. Evaluation of Plasmapheresis vs Immunoglobulin as First Treatment After Ineffective Systemic Corticosteroid Therapy for Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatol. 2023. PMID: 36884227. doi:10.1001/jamadermatol.2023.0035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。